Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Zumedha | Equity Research

Research · Analysis · Insights

Zumedha | Equity Research

Research · Analysis · Insights

  • Home
  • Stocks Analysis
    • Metals
    • Auto Sector
      • Auto Components
    • Banking & Finance
    • Aviation
    • Power & Energy
      • Cables & Wires
      • Battery Industries
    • IT & Tech
      • IT Services
      • Technology
      • BioTech Stocks
      • Bio Science
    • Infrastructure Sector
    • Telecom
    • Hotels & Hospitality
    • Travel & Hospitality
    • Healthcare
      • Pharmaceutical Industry
    • Quick COmmerce
    • Consumer Services
    • EMS Stocks
  • Mutual Funds
    • SmallCap Mutual Funds
    • Multicap MFs
    • SIP Calculator
  • Master Class
  • Tools
    • MF Return Calculator
    • Loan Calculator
    • Tax Calculator
  • Home
  • Stocks Analysis
    • Metals
    • Auto Sector
      • Auto Components
    • Banking & Finance
    • Aviation
    • Power & Energy
      • Cables & Wires
      • Battery Industries
    • IT & Tech
      • IT Services
      • Technology
      • BioTech Stocks
      • Bio Science
    • Infrastructure Sector
    • Telecom
    • Hotels & Hospitality
    • Travel & Hospitality
    • Healthcare
      • Pharmaceutical Industry
    • Quick COmmerce
    • Consumer Services
    • EMS Stocks
  • Mutual Funds
    • SmallCap Mutual Funds
    • Multicap MFs
    • SIP Calculator
  • Master Class
  • Tools
    • MF Return Calculator
    • Loan Calculator
    • Tax Calculator
Close

Search

Zumedha | Equity Research

Research · Analysis · Insights

Zumedha | Equity Research

Research · Analysis · Insights

  • Home
  • Stocks Analysis
    • Metals
    • Auto Sector
      • Auto Components
    • Banking & Finance
    • Aviation
    • Power & Energy
      • Cables & Wires
      • Battery Industries
    • IT & Tech
      • IT Services
      • Technology
      • BioTech Stocks
      • Bio Science
    • Infrastructure Sector
    • Telecom
    • Hotels & Hospitality
    • Travel & Hospitality
    • Healthcare
      • Pharmaceutical Industry
    • Quick COmmerce
    • Consumer Services
    • EMS Stocks
  • Mutual Funds
    • SmallCap Mutual Funds
    • Multicap MFs
    • SIP Calculator
  • Master Class
  • Tools
    • MF Return Calculator
    • Loan Calculator
    • Tax Calculator
  • Home
  • Stocks Analysis
    • Metals
    • Auto Sector
      • Auto Components
    • Banking & Finance
    • Aviation
    • Power & Energy
      • Cables & Wires
      • Battery Industries
    • IT & Tech
      • IT Services
      • Technology
      • BioTech Stocks
      • Bio Science
    • Infrastructure Sector
    • Telecom
    • Hotels & Hospitality
    • Travel & Hospitality
    • Healthcare
      • Pharmaceutical Industry
    • Quick COmmerce
    • Consumer Services
    • EMS Stocks
  • Mutual Funds
    • SmallCap Mutual Funds
    • Multicap MFs
    • SIP Calculator
  • Master Class
  • Tools
    • MF Return Calculator
    • Loan Calculator
    • Tax Calculator
Close

Search

Home/IT Services/Latent View Share Valuation Analysis April 2026
IT ServicesTechnology

Latent View Share Valuation Analysis April 2026

By Zumedha Research Team on April 7, 2026 8 Min Read
LatentView Analytics — Equity Research Report

Zumedha Equity Research  |  Indian Small-Cap Technology  |  April 2026

LatentView Analytics

Where Data Meets Capital — A Comprehensive Investment Analysis

NSE LATENTVIEW
CMP ₹309.55 (as on 05 Apr 2026)
52W High ₹517.50
52W Low ₹248.00
Market Cap ₹5,165 Cr
P/E 29.65×
Sector IT — Analytics
ACCUMULATE
Section 01

Business Overview

LatentView Analytics is India’s most-focused pure-play data analytics firm — a niche, founder-led company built on the conviction that the intelligence layer in enterprise technology spending is the most defensible and fastest-growing one.

Founded in 2006 by Venkat Viswanathan, Ramesh Hariharan, and Pramad Jandhyala and headquartered in Chennai, LatentView listed on NSE and BSE on 23 November 2021 at ₹197 per share. It operates as a globally distributed analytics boutique, serving clients across five core verticals: Technology, BFSI, Consumer Packaged Goods (CPG) & Retail, Industrials, and an emerging Healthcare vertical.

The company’s service portfolio spans the full analytics value chain — from data engineering and migration at the foundation layer, to advanced predictive and causal analytics and generative AI solutions at the intelligence layer, to data visualization and consumer insights at the action layer. As of Q3 FY26, the firm serves 30+ Fortune 500 clients with a headcount of approximately 1,200 professionals across offices in Chennai, Princeton (NJ), San Jose (CA), London, Singapore, and Germany.

The business model is subscription/retainer-heavy with a strong bias toward multi-year, high-renewal-rate engagements. This creates an annuity quality to revenues that belies the company’s small-cap classification. The promoter group, led by Venkat Viswanathan (Chairman), holds 65.1% of the company — a signal of strong long-term alignment with minority shareholders.

Founded 2006 Chennai, Tamil Nadu
Listed Nov 2021 BSE & NSE
Employees ~1,200 As of Aug 2025
Fortune 500 Clients 30+ Across 5 verticals
Promoter Holding 65.1% High alignment
Global Offices 6 India, US, UK, SG, DE
TTM Revenue ₹1,004 Cr ~$115M USD
TTM Net Profit ₹198 Cr Healthy but compressing
Section 02

Historical Financials

LatentView’s financial history tells a story of two phases: explosive post-listing growth (FY22–FY25) as global enterprise analytics adoption accelerated, followed by a maturation phase where revenue growth has remained robust (~22% 5-year CAGR) but margin compression has emerged due to wage normalisation, compliance costs, and investment in AI capabilities.

PeriodRevenue (₹ Cr)YoY GrowthNet Profit (₹ Cr)PAT MarginEPS (₹)
FY22440—10423.6%5.02
FY23567+28.9%13123.1%6.33
FY24642+13.2%15824.6%7.65
FY25917+42.8%17419.0%8.43
Q1 FY26232 (qtrly)+35.3% YoY5122.0%2.47
Q2 FY26258 (qtrly)+23.3% YoY4416.1%2.15
Q3 FY26278 (qtrly)+22.0% YoY5018.0%2.43
FY26E (Full Year)~1,030–1,050~15–18%~200–210~19–20%~9.7–10.2

Key Observations: The 5-year revenue CAGR stands at an impressive ~22.7% vs. the IT services industry average of ~11%. However, PAT margins have compressed from a peak of ~24.6% in FY24 to the 16–19% range in FY26, driven by (1) a one-time labour code compliance catch-up of ₹4.6 Cr in Q2 FY26, (2) an 11.1% spike in payroll and benefits costs, and (3) softness in the CPG & Retail vertical due to project delays. Revenue has grown for 8+ consecutive quarters — a streak that underscores the structural tailwind beneath the margin noise.

“Despite sector-specific turbulence in CPG and retail, LatentView delivered its 12th consecutive quarter of sequential dollar revenue growth in Q3 FY26 — a testament to the stickiness of its client relationships.”
Section 03

DCF Valuation

We model a 10-year free cash flow discounted at a WACC of 12% with a terminal growth rate of 5%, consistent with our analytical framework for mid-cap Indian IT services. Given LatentView’s zero-debt balance sheet, cost of equity approximates WACC. We assume base-case revenue growth of 20% for FY27-FY29, tapering to 15% in FY30-FY31 and 10% thereafter as the business scales.

DCF Model — Base Case (WACC: 12% | Terminal Growth: 5% | 10-Year FCF)

₹340–360
₹430–470
₹220–250
₹9.8–10.2
29.65×
30–38×

Assumptions: FY27–29 revenue CAGR 18–22%; EBITDA margins recovering to 22–24%; capex intensity <3% of revenue (asset-light); terminal growth supported by structural AI analytics demand. No debt on balance sheet; cash-rich (₹900+ Cr estimated). Note: The market currently prices LatentView at ₹309.55 — a discount of ~12–15% to base-case intrinsic value, creating a margin of safety for long-term investors.

Section 04

Buy Range — Entry Zones

Based on our DCF analysis, peer multiples, and technical support levels, we define three buy zones for long-term investors:

🟢 Strong Buy ₹240–270 Near 52-week low support. Deep value with 30%+ upside to base IV. Aggressive accumulation zone.
🟢 Accumulate ₹270–320 Current market price zone. Reasonable margin of safety. Systematic SIP/staggered buying recommended. CMP ₹309 falls here.
🟢 Fair Value ₹320–360 Approaching DCF fair value. Hold or buy small tranches on dips within this band.
Section 05

Buy Scenario Analysis

🐻 Bear Case

Revenue growth decelerates to 10–12%. Margins stay compressed at 15–17% due to prolonged CPG weakness and AI investment drag. Major client concentration risk materializes. New US protectionism impacts offshore billing.

Target: ₹220–250 | Downside: ~20%

📊 Base Case

Revenue grows 18–22% over FY27–FY29. Margin recovery to 21–23% as payroll normalises. BFSI and Technology verticals continue strong growth. Databricks partnership contributes incremental revenue. AI products gain traction.

Target: ₹360–400 | Upside: ~20–30%

🐂 Bull Case

AI agents and GenAI platforms become a material revenue driver (15%+ of mix). New client wins in healthcare (Healtheon AI investment) add a fourth growth engine. Margins expand to 24–26%. Re-rating to 40–45× P/E as narrative shifts to “analytics platform.”

Target: ₹480–530 | Upside: ~55–70%
Section 06

Sell Range — Exit Zones

We define three exit zones for investors managing position sizing and booking profits. These levels assume current fundamentals and do not account for a structural re-rating scenario (which would raise these thresholds).

🔴 Reduce ₹430–470 Approaching analyst consensus target of ₹495–577. Start trimming 20–30% of position. Valuation getting stretched vs peers.
🔴 Exit ₹480–540 Near or above 52-week high of ₹517.50. P/E exceeds 50×. Book majority of position unless fundamental re-rating is confirmed.
🔴 Avoid / Short > ₹560 Unsupported by fundamentals at current growth rate. P/E >55×. Full exit; watch for macro or client concentration triggers.
Section 07

Sell Scenario Analysis

⚠ Overvalued

Market re-rates the stock to 45–55× P/E on AI narrative hype. Revenue growth slows to <15% while stock continues to rally. Valuation disconnect from fundamentals. Time to reduce.

Signal: P/E >48× and revenue guidance cut

🚨 Exit Trigger

Key client loss (top 3 clients = ~40% revenue). CFO resignation not reversed. Back-to-back quarterly revenue misses. Margin falls below 14% for two consecutive quarters.

Signal: 2+ consecutive guidance misses

❌ Structural Break

Loss of Databricks or Microsoft partnership. US regulatory clampdown on data analytics outsourcing. Fundamental shift in client spending to in-house AI teams. Promoter stake sale at material discount.

Signal: Revenue decline for 2+ quarters
Section 08

Future Growth & Earnings Outlook

LatentView’s growth thesis is anchored on three structural tailwinds: the democratisation of enterprise data infrastructure, the AI/GenAI spending wave, and the increasing complexity of consumer analytics that benefits specialist firms over generalist IT vendors.

AI Agents Strategy: Management has explicitly articulated a vision to deploy digital AI agents that replace physical workforce functions for clients. This is not a distant aspiration — the company is already piloting agentic AI frameworks in client environments, and the $3 million SAFE note investment in Healtheon AI (April 2026) for AI-driven Revenue Cycle Management signals a move into healthcare analytics as a new vertical.

Databricks Partnership: The company’s deep integration with Databricks — the leading data lakehouse platform — is a significant moat builder. As enterprises migrate to Databricks, LatentView is positioned as the preferred analytics implementation partner. Management has signalled that this partnership could “significantly enhance revenue streams” in FY27 and beyond.

BFSI Strength: Financial services has emerged as the fastest-growing vertical, compensating for CPG/Retail softness. Risk analytics, fraud detection, and portfolio intelligence are high-margin, recurring revenue streams with low client switching probability.

YearRevenue Est. (₹ Cr)GrowthEBITDA MarginPAT Est. (₹ Cr)EPS (₹)
FY26E1,030–1,050~15%~22%200–2109.7–10.2
FY27E1,230–1,270~20%~23%240–26011.6–12.6
FY28E1,470–1,540~20–22%~24%295–32514.3–15.7
FY29E1,730–1,850~18–20%~24–25%355–39017.2–18.9

At CMP of ₹309.55, the stock trades at ~30× FY26E EPS and ~25× FY27E EPS — attractive multiples for a company growing at 18–22% with a debt-free balance sheet, ₹900+ Cr in cash/equivalents, and expanding addressable markets in AI analytics.

Section 09

Risks & Catalysts

📈 Catalysts (Bull Case Drivers)

  • AI Platform Monetisation: Proprietary AI agents and GenAI solutions gaining client adoption could drive 3–5% margin uplift.
  • Databricks Revenue: Partnership-led revenues could add ₹100–150 Cr incremental by FY28.
  • Healthcare Vertical: Healtheon AI investment opens a $50B+ US healthcare RCM market as a new growth engine.
  • BFSI Upcycle: Global financial services analytics spend rising 15%+ annually; LatentView is well-positioned.
  • Client Count Expansion: Adding mid-market clients alongside Fortune 500 reduces concentration risk and drives total revenue density.
  • Margin Recovery: Labour code compliance one-offs normalising in FY27; operating leverage on fixed cost base improves margins by 200–300bps.

📉 Risks (Bear Case Threats)

  • Client Concentration: Top 5 clients likely represent ~40–50% of revenues. Loss of even one key Tech/BFSI client materially impacts growth.
  • CPG/Retail Weakness: Project delays in this vertical (Q2–Q3 FY26) could persist as global FMCG companies cut analytics budgets.
  • In-House AI Capability: Large tech clients (Microsoft, Google, Meta) building sophisticated internal analytics platforms, potentially reducing outsourcing need.
  • Attrition & Talent: Analytics talent remains scarce and expensive. High attrition among senior data scientists is a structural risk.
  • Receivables Creep: Operating profit conversion to cash has been flagged as a concern by some analysts; receivables rising faster than sales warrants monitoring.
  • Valuation Re-de-rating: If growth fails to re-accelerate to 20%+ consistently, the market may de-rate to 20–22× P/E, implying 25–30% downside from CMP.
Section 10

Peer Comparison

LatentView occupies a unique niche as India’s only listed pure-play analytics company. Its closest listed peers are broader IT services firms with analytics practices (EXL Service, Coforge), while its closest business model comparables (Fractal Analytics, Tredence) remain private.

CompanyMarket CapRevenue (TTM)PAT MarginP/ERevenue CAGR (3Y)Focus
LatentView Analytics₹5,165 Cr₹1,004 Cr~19%29.7×~22%Pure-play Analytics
EXL Service Holdings~$4.5B USD~$2.2B USD~12%28–32×~15%Analytics + BPO
Coforge Ltd~₹42,000 Cr~₹11,000 Cr~8%40–45×~25%IT Services (BFSI-led)
Mphasis Ltd~₹48,000 Cr~₹14,500 Cr~15%30–35×~12%Digital IT Services
Zensar Technologies~₹14,000 Cr~₹5,800 Cr~11%25–28×~10%IT Services
Fractal Analytics (pvt.)~$1B+ USD est.~$400M USDN/AN/A~20%Pure-play Analytics (pvt.)
Key TakeawayLatentView trades at a discount to midcap IT peers on P/E despite superior revenue CAGR and higher PAT margin. Its pure-play analytics moat and debt-free balance sheet justify a premium to generalist IT firms.

◆ ◆ ◆
Final Verdict — Research Conclusion

ACCUMULATE | Target: ₹380–400 | Horizon: 18–24 Months

LatentView Analytics represents one of the most compelling structural growth stories in Indian small-cap technology — a pure-play analytics firm with a debt-free balance sheet, 65% promoter skin in the game, Fortune 500 client relationships, and a front-row seat to the enterprise AI analytics revolution. The stock has corrected ~40% from its 52-week highs, creating a meaningful margin of safety relative to our base-case DCF of ₹340–360 and consensus analyst targets of ₹495–578. Near-term margin pressure from CPG softness and labour code compliance is transient, not structural. The Databricks partnership, Healtheon AI investment, and agentic AI strategy position the company for accelerating growth into FY28. We recommend systematic accumulation in the ₹270–330 band for investors with an 18–24 month horizon, with a 20–25% position stop-loss below ₹230.

DISCLAIMER: This report is prepared for informational and educational purposes only, intended for publication as a WordPress article. It does not constitute investment advice, a solicitation to buy or sell securities, or a recommendation by any licensed financial advisor. All financial data is sourced from publicly available information (NSE, Screener.in, Tickertape, company filings) and is believed to be accurate as of April 2026 but is not independently verified. Equity investments are subject to market risks, including the possible loss of principal. Readers should conduct their own due diligence and consult a SEBI-registered investment advisor before making any investment decisions. The author(s) may or may not hold positions in LATENTVIEW at the time of publication. Past performance is not indicative of future results. EPS and valuation estimates are forward-looking and subject to change based on company performance, macroeconomic conditions, and market dynamics.
Author

Zumedha Research Team

Follow Me
Other Articles
Previous

Persistent Systems Value Analysis April 2026

Next

Buy vs Accumulate Rating in Stocks: Key Differences Every Investor Must Know

Legal Disclaimer Investment Research & Information

Not Investment Advice. All content published on this website — including stock analyses, mutual fund reviews, DCF models, valuation estimates, buying zones, and commentary — is created for our own educational, internal research and informational purposes only. Nothing on this website constitutes financial, investment, legal, or tax advice, nor a solicitation or recommendation to buy, sell, or hold any security or financial instrument.

No Guarantees. It is advised clearly and categorically not o follow these analysis and information blindly for your equity investement purpose as Equity investments and mutual funds are subject to market risks. Past performance is not indicative of future results. All DCF models, fair value estimates, and scenario analyses are based on publicly available data and the author's independent assumptions and may prove materially incorrect. The author/s or owners of this website/portal do not are not liable in whatsoever manner for any positive or negative outcome from your own investment endeavorsYou may lose part or all of your invested capital.

Do Your Own Research. Readers are strongly advised to consult a SEBI-registered investment advisor and conduct their own due diligence before making any investment decision. The author may or may not hold positions in securities discussed on this website.

No Obligations. We, the author/ the publisher/ anybody associated with Zumedha.com does not guarantee the accuracy, adequacy or completeness of any information/data and is not responsible for any errors or omissions or for the results obtained from the use of such information/data. Zumedha.com or anyone involved with zumedha.com will not accept any liability for loss or damage as a result of reliance on the Estimates data. It does not subscribe or endorse any of the services and/or content offered by such third party.

Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing.
This website is not registered as an Investment Adviser under SEBI (Investment Advisers) Regulations, 2013. All views are personal and for informational purposes only.
© 2026 · All Rights Reserved · For Educational Use Only. RESEARCH · ANALYSIS · INSIGHTS